Thrombin–fibrinogen interaction

The thrombin–fibrinogen interaction is the terminal enzymatic step in the blood coagulation cascade, characterized by the thrombin-mediated cleavage of fibrinogen into fibrin. Thrombin, a serine protease (Factor IIa), recognizes and binds to fibrinogen (Factor I) at specific sites, primarily through its active site and exosite I, to release fibrinopeptides A and B (Di Cera, 2008). This cleavage triggers the spontaneous polymerization of fibrin monomers into an insoluble mesh, which stabilizes the primary platelet plug and forms a mature blood clot (Weisel, 2005). Pathological activation of this interaction is a hallmark of thrombotic disorders, including deep vein thrombosis and acute coronary syndromes, where excessive clot formation leads to vascular occlusion (Wolberg, 2007). Therapeutic agents targeting this interaction, such as direct thrombin inhibitors (e.g., dabigatran, bivalirudin), work by sterically or competitively blocking thrombin's ability to process fibrinogen (StatPearls, 2023). While highly effective as anticoagulants, these drugs necessitate careful monitoring due to the inherent risk of major bleeding episodes resulting from impaired hemostasis.

Other names

Thrombin-mediated fibrinogen cleavageFibrinogen-to-fibrin conversionThrombin-fibrinogen complex formationProteolytic activation of fibrinogen

Direct or indirect inhibition of thrombin's catalytic activity or exosite binding to prevent the proteolytic conversion of fibrinogen into fibrin monomers.